Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,6 USD | -7,51% | -27,60% | -31,33% |
Vakgebied
Aantal werknemers: 10
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01-03-20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-03-20 |
Mutya Harsch
LAW | General Counsel | 50 | 01-03-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10-09-20 |
Steven Basta
BRD | Director/Board Member | 59 | 01-01-15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01-03-20 |
Director/Board Member | 62 | 01-03-19 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 01-03-20 |
Director/Board Member | - | 01/01 | |
Sharon Barbari
BRD | Director/Board Member | 70 | 01-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 14 528 247 | 13 299 165 ( 91,54 %) | 0 | 91,54 % |
Bedrijfsgegevens
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-31,33% | 23,25 mln. | |
+54,61% | 811 mld. | |
+44,25% | 640 mld. | |
-6,33% | 353 mld. | |
+20,62% | 333 mld. | |
+10,44% | 302 mld. | |
+18,45% | 246 mld. | |
+2,09% | 225 mld. | |
+13,03% | 218 mld. | |
+8,61% | 168 mld. |
- Beurs
- Aandelen
- Koers VYNE
- Onderneming VYNE Therapeutics Inc.